Abstract:There is still no effective drug treatment available for Charcot-Marie-Tooth disease (CMT). Current management relies on rehabilitation therapy, surgery for skeletal deformities, and symptomatic treatment. The challenge is to find disease-modifying therapies. Several approaches, including gene silencing (by means of ASO, siRNA, shRNA, miRNA, CRISPR-Cas9 editing), to counteract the PMP22 gene overexpression in the most frequent CMT1A type are under investigation. PXT3003 is the compound in the most advanced phase for CMT1A, as a second phase-III trial is ongoing. Gene therapy to substitute defective genes (particularly in recessive forms associated with loss-of-function mutations) or insert novel ones (e.g., NT3 gene) are being developed and tested in animal models and in still exceptional cases have reached the clinical trial phase in humans. Novel treatment approaches are also aimed at developing compounds acting on pathways important for different CMT types. Modulation of the neuregulin pathway determining myelin thickness is promising for both hypo-demyelinating and hypermyelinating neuropathies; intervention on Unfolded Protein Response seems effective for rescuing misfolded myelin proteins such as MPZ in CMT1B. HDAC6 inhibitors improved axonal transport and ameliorated phenotypes in different CMT models. Other potential therapeutic strategies include targeting macrophages, lipid metabolism, and Nav1.8 sodium channel in demyelinating CMT and the P2×7 receptor, which regulates calcium influx into Schwann cells, in CMT1A. Further approaches are aimed at correcting metabolic abnormalities, including the accumulation of sorbitol caused by biallelic mutations in the sorbitol dehydrogenase (SORD) gene and of neurotoxic glycosphingolipids in HSN1.

Current Treatment Methods for Charcot–Marie–Tooth Diseases

Clinical and Genetic Characteristics of Charcot-Marie-Tooth Disease

Recent advances in the treatment of Charcot‐Marie‐Tooth neuropathies

[Analysis of the Pathological Features and Gene Mutations of Chinese Patients with Charcot-Marie-Tooth Disease].

Charcot-Marie-Tooth: From Molecules to Therapy

Challenges in Treating Charcot-Marie-Tooth Disease and Related Neuropathies: Current Management and Future Perspectives

Author Response for "genetic Spectrum and Clinical Profiles in a Southeast Chinese Cohort of Charcot‐Marie‐Tooth Disease"

New developments in Charcot-Marie-Tooth neuropathy and related diseases

Gene therapy and other novel treatment approaches for Charcot-Marie-Tooth disease

Genetic approaches and pathogenic pathways in the clinical management of Charcot-Marie-Tooth disease

Advances in the Study of Genetic Characteristics and Molecular Mechanisms in Charcot-Marie-Tooth Disease

Analysis of the clinical, electrophysiological and histopathological features of Chinese Charcot-Marie Tooth disease patients with small heat-shock protein 27 gene mutation

The characteristics of gene mutations in Chinese patients with Charcot-Marie-Tooth disease]

Emerging Therapies for Charcot-Marie-Tooth Inherited Neuropathies

Axonal Charcot-Marie-Tooth Disease: from Common Pathogenic Mechanisms to Emerging Treatment Opportunities

Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies

Understanding Genetic Pathways, Disease Models, and Potential Therapeutic Approaches

Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?

Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives

Advances in genetic studies of Charcot-Marie-Tooth disease type 4 (CMT4)

Research Progress in the Mouse Models of Charcot-Marie-Tooth Disease Type 2 (CMT2)